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osai-Dorfman disease (RDD) is a benign
histiocytic proliferation that most commonly
presents with painless bilateral lymphade-
nopathy and constitutional symptoms such as fever,
fatigue, and night sweats.1 RDD is considered by
many to be a reaction pattern with several different
manifestations, especially as clonality has not been
documented to support it representing a neoplasm
per se. Classic histologic features include histiocytes
that are S100 protein positive, are CD1a, and
demonstrate emperipolesis. Cutaneous lesions can
occur in about 10% of patients, however, RDD
limited only to cutaneous involvement is particularly
rare.2,3 Moreover, concomitant cutaneous RDD
(CRDD) and bone RDD has rarely been reported in
the English-language literature.4,5 Here, we pre-
sented a case of CRDD on the scalp with underlying
bony involvement.
CASE REPORT
A 53-year-old African Americanwoman presented
for evaluation of asymptomatic growths on her
scalp that had been progressively enlarging over a
6-month period of time. She denied any constitu-
tional symptoms and her medical, family, and
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cluster of 5 erythematous to yellow nodules ranging
in size from 0.5 to 1.5 cm each on the midline vertex
of the scalp (Fig 1, A). No lymphadenopathy was
appreciated on physical examination. Previous eval-
uation by an outside provider included a deep shave
biopsy specimen interpreted as granulation tissue
with inflammation, deemed negative for malignancy.
Bacterial and fungal stains were negative. To rule out
any lymphoproliferative process, a subsequent exci-
sional biopsy specimen revealed a dense dermal
infiltrate of histiocytes with abundant light eosino-
philic cytoplasm and distinct nucleoli extending
from the papillary to the reticular dermis (Fig 1, B
and C ). Foam cells, lymphoid aggregates, focally
prominent plasma cells, and sparse intermixed
granulocytes were noted. Immunohistochemical
stains demonstrated uniform, strong positivity for
S100 protein in the histiocytic cells, and highlightedresearch component of the Arkansas Tobacco Settlement Pro-
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Fig 1. Cutaneous Rosai-Dorfman disease. A, The clinical manifestation on presentation
included erythematous pustular nodules on the midline vertex of the scalp. B, Histologic
examination revealed a histiocytic and lymphocytic infiltrate. C, High magnification reveals
histiocytes with abundant eosinophilic to foamy cytoplasm engulfing other inflammatory cells
(emperipolesis). Plasma cells are also part of the infiltrate. (B and C, Hematoxylin-eosin stain;
original magnifications: B, 320; C, 3400.) D, Numerous histiocytes demonstrating emperipol-
esis. (S100 stain; original magnification: 340.)
Fig 2. BRAF V600E (c. 1799 T[A) sequencing. Chromato-
gram represents the relevant Rosai-Dorfman sample
nucleotide sequence; reference sequence represents the
wild type BRAF gene (Homo sapiens BRAF proto-
oncogene, National Center for Biotechnology Information,
National Institutes of Health). Highlighted nucleotide in
yellow denotes the position of interest (c. 1799) with lack
of T[A nucleotide transversion.
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negative in the lesional cells. Interestingly, magnetic
resonance imaging of the brain indicated the under-
lying bony involvement with a small focus of full-
thickness calvarial erosion and no intracranial lesion
was appreciated. A computed tomography scan of
the neck, chest, abdomen, and pelvis was unreveal-
ing. Lactate dehydrogenase and erythrocyte sedi-
mentation rate were elevated. Both urine and serum
protein electrophoresis revealed normal findings.
Recently, BRAFV600E mutation has been detected
in Langerhans cell histiocytosis (LCH) and Erdheim-
Chester disease, but not in other histiocytic disorders
such as juvenile xanthogranuloma and RDD.6-8
However, it is unlikely the RDD cases included in
the studies were cases with concurrent skin andbone involvement, simply because of the rarity of
this condition. Given this unusual bony involvement
in our patient, we decided to examine whether our
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cases of RDD, a wild type BRAF was revealed by
direct DNA sequencing of extracted genomic DNA as
described previously7 (Fig 2).
DISCUSSION
RDD limited only to the skin, referred to as
‘‘cutaneous’’ RDD, is a rare variant and involves a
distinct demographic distribution.1,3 Although sys-
temic RDD ismost common in Caucasian and African
American men younger than 20 years, CRDD is
usually found in Caucasian and Asian women in
the fifth decade of life.1 CRDD is especially rare in
African Americans, as seen in our patient.1 The
clinical presentation of CRDD varies from solitary
or multiple erythematous, yellow, or brown papules,
nodules, or plaques that typically involve the torso or
face. CRDD presenting on the scalp is rare with only
4 cases reported.9-12 The clinical differential diag-
nosis includes necrobiotic xanthogranuloma, which
can present as a yellow plaque, and multicentric
reticulohistiocytosis. Primary RDD of the bone is
particularly uncommon. It typically affects long
bones and causes lytic bone lesions.4 Interestingly,
a few cases with RDD in both cutaneous and bony
involvement have been reported.5 Yoon et al5 re-
ported a patient with an initial bone lesion in the
fibula who developed subcutaneous lesions on up-
per extremities several months later. Similar to our
patient, 2 patients who presented with subcutaneous
lesions on the scalp and underlying calvarial RDD
have been reported recently10,13; 1 of the patients
also developed a lesion in the spine later.13 Although
it is unlikely the cutaneous lesion was derived from
RDD of the bone in our patient, it is impossible to
discriminate whether cranial erosion is a result of the
local destruction of CRDD or concomitant primary
RDD of the bone involving the overlying skin
without obtaining a sample from cranium.
Nevertheless, the patient will need to be followed
up closely with imaging studies to monitor the
development of additional bone lesions.
Unlike some reported cases of LCH,6-8 there is no
BRAFV600E detected even though there is bony
involvement in our patient, suggesting a distinct
cause in CRDD as compared with LCH. The lack of
BRAFV600E mutation in our patient also further
supports that RDD may represent a reactive, rather
than neoplastic, condition, and is clinically significant
as it illustrates no role for targeted therapy with
BRAF/mitogen-activated protein kinase pathway in-
hibitors. Although the exact origin of RDD is un-
known, it is postulated to reflect a hyperstimulation
of humoral immunity,2,3,14 which is evidenced
by coexistence of RDD with autoimmune disease,hematologic malignancies, and postinfectious
conditions. Histology plays an essential role in
obtaining a definitive diagnosis. On low-power
magnification, CRDD is recognized by a dense
dermal infiltrate of foamy to pink histiocytes. The
large, polygonal histiocytes have voluminous cyto-
plasm and vesicular nuclei. An intact cell engulfed
within the cytoplasm of a histiocyte, termed ‘‘emper-
ipolesis,’’ is classically identified in RDD.1,2
Immunophenotypically, the histiocytes in RDD ex-
press S100 protein but are negative for CD1a. These
histopathologic findings and the immunophenotype
are essential to differentiate RDD from LCH and
malignant histiocytosis, particularly when there is
bony involvement. In contrast to RDD, LCH is
composed of clusters and sheets of ovoid histiocytoid
cells with a reniform or coffee beaneshaped nucleus
that often invade and extend into the epidermis,
frequent accompanying eosinophils, and CD1a and/
or Langerin protein expression in the histiocytes.
Although there is no broad consensus on best
practice therapy for CRDD, a variety of therapeutic
interventions have been reported, including topical
and systemic corticosteroids, acyclovir, interferon,
antibiotics, imatinib mesylate, retinoids, dapsone,
methotrexate, thalidomide, cryotherapy, surgical
excision, and radiation.1,3,14,15 Although some cases
may persist and progress despite treatment, the
prognosis is generally favorable, with many reported
cases following a generally indolent course with
spontaneous self-remittance within 3 years.1,14 After
detailed review of treatment options, our patient
elected for surgical excision of the lesions on the
scalp and declined radiation.
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